- Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO<figure><div><img src="https://imgproxy.divecdn.com/WuH_AaE1tfJ0k6kCbc3Pl9229iGeCCh2cRL_fgDY5lg/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TYXJlcHRhX1Bob3RvXzEuSlBH.webp"/><…BioPharma Dive · 21h ago↗ source
- RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPACRare disease biotech Oak Hill is headed to the Nasdaq through a SPAC merger with RA Capital-sponsored Research Alliance Corporation III (RACC) to fund a rare genetic disease candidate.Fierce Biotech · 22h ago↗ source
- STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executiveThe beleaguered Sarepta Therapeutics named Michael Severino, who previously led Tessera Therapeutics, as its new CEO.